ArticleBMC research notes2026
Exploring plasma microRNA profiling and signaling pathways in comorbidity-free sickle cell anemia: a pilot case-control study.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveSickle cell anemia (SCA) is associated with substantial end‑organ morbidity, yet the circulating microRNA (miRNA) landscape in clinically stable, comorbidity‑free adults with SCA is poorly defined. This pilot case-control study with a limited sample size aimed to characterize a baseline plasma miRNA signature of SCA by comparing comorbidity‑free adults with SCA and strictly matched controls, with findings intended to be hypothesis‑generating.
resultsUsing the Mass General Brigham Biobank, we identified 4 adults with HbSS SCA and 12 HbAA controls, matched 1:3 by age, sex, and estimated glomerular filtration rate. All participants were free of diabetes, hypertension, cardiovascular disease, chronic kidney disease, and proteinuria. Plasma small RNA sequencing identified 41 differentially expressed miRNAs in SCA versus controls (2 upregulated, 39 downregulated; p < 0.05). These miRNAs mapped to 99 enriched KEGG pathways, including PI3K/Akt, MAPK, and Hippo signaling, which are implicated in endothelial dysfunction, vasculopathy, and organ complications relevant to SCA. These preliminary, hypothesis‑generating findings from a small pilot cohort support the presence of subclinical vascular and inflammatory pathway dysregulation in comorbidity‑free SCA and provide candidate miRNAs and pathways for future validation in larger, independent cohorts. These results represent unvalidated discovery signals and should not be interpreted as a definitive miRNA profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.